What are the recommended dosing, mechanism of action, side effects, and contraindications of Miralax (polyethylene glycol 3350) for treating constipation in adults and children?

Polyethylene Glycol 3350 (MiraLAX) for Constipation

For adults with chronic constipation, initiate polyethylene glycol 3350 at 17 grams once daily mixed in 4–8 ounces of liquid and continue for at least 1–2 weeks to achieve optimal effect; this regimen carries a strong recommendation from the 2023 AGA-ACG guideline based on moderate-certainty evidence. 1, 2

Mechanism of Action

• PEG 3350 is a long-chain polymer of ethylene oxide that exerts a purely osmotic effect by binding water molecules in the intestinal lumen, thereby retaining water in the stool and softening its consistency. 2
• Unlike secretagogues or stimulant laxatives, PEG 3350 does not stimulate colonic smooth-muscle contractions or activate ion channels—its laxative action is entirely physical water retention. 2

Adult Dosing and Administration

Standard Dosing

• The recommended dose is 17 grams once daily, dissolved in a minimum of 4 ounces (preferably 8 ounces) of any beverage including water, juice, soda, coffee, or tea. 2, 3
• Bowel movements typically occur within 2 to 4 days (48–96 hours) of initiating therapy. 3
• Continue therapy for at least 1–2 weeks to achieve optimal therapeutic effect, as efficacy peaks during the second week of treatment. 2, 3

Dose Titration

• If the standard 17-gram daily dose is insufficient after 2 weeks of optimal dosing with confirmed adequate hydration, increase the dose (e.g., to 34 grams daily or higher) based on individual response and tolerability. 2
• No definitive maximum dose has been established; dosing should be adjusted according to clinical response. 2
• Higher single doses (68 grams) have been studied for rapid relief within 24 hours, producing an average of 2.2 bowel movements in 24 hours without adverse reactions. 4

Critical Implementation Point

• Insufficient liquid volume is the most common cause of treatment failure. Patients must dissolve the powder in at least 4 ounces (preferably 8 ounces) of fluid and maintain adequate daily fluid intake throughout the day beyond just the mixing liquid, as PEG requires water to work osmotically. 2

Clinical Efficacy

• PEG 3350 increases complete spontaneous bowel movements by 2.9 per week compared with placebo. 2
• It increases total spontaneous bowel movements by 2.3 per week versus placebo. 2
• 312 additional patients per 1,000 achieve responder criteria (≥3 spontaneous bowel movements per week) compared with placebo. 2
• 454 additional patients per 1,000 report global symptom relief compared with placebo. 2
• Treatment success (relief of constipation criteria for ≥50% of treatment weeks) occurs in 52% of patients versus 11% with placebo. 2
• Therapeutic response is durable for up to 6 months and has been evaluated for as long as 52 weeks, supporting long-term maintenance therapy when needed. 2

Managing Inadequate Response

• For persistent constipation after 3–4 days of optimal PEG therapy with adequate hydration, add a stimulant laxative (e.g., senna 8.6–17.2 mg daily or bisacodyl 5–10 mg daily) to exploit complementary mechanisms—PEG softens stool via osmotic water retention while stimulants enhance colonic motility. 2, 5
• The combination of PEG 3350 with senna or bisacodyl is endorsed by the AGA and NCCN for refractory constipation. 2

Pediatric Dosing

Functional Constipation in Children

• For children with functional constipation, the average effective dose is 0.7–0.8 grams per kilogram per day, with an initial starting dose of approximately 1 gram per kilogram per day. 5, 6, 7
• Parents should adjust the dose to yield 1 to 2 soft, painless stools per day. 7
• PEG 3350 is effective and safe for use in children for 6–12 months or more, with an average treatment duration of 8.4 months in pediatric studies. 5
• Constipation was relieved in 85% of children with short-term therapy (≤4 months) and in 91% with long-term therapy (≥6 months). 7

Bowel Preparation for Colonoscopy

• For pediatric bowel preparation, administer 1.5 grams per kilogram per day for 4 days (maximum 100 grams per day), combined with a clear-liquid diet on the final day. 5
• Alternative single-day preparations are also effective, though less studied in children. 5

Pediatric Administration Tips

• Mix the powder in at least 4–8 ounces of liquid; juices with sorbitol content provide a synergistic osmotic effect. 5
• If no bowel movement occurs after 3–4 days, add a bisacodyl suppository (10 mg) or glycerin suppository while continuing PEG. 5
• For persistent constipation, consider adding an oral stimulant laxative (senna or bisacodyl) to the PEG regimen, administered approximately 30 minutes after meals to exploit the gastro-colonic reflex. 5

Pediatric Safety Considerations

• Rule out bowel obstruction or paralytic ileus before initiating therapy. 5
• Check for fecal impaction, which may require manual disimpaction or enema before starting PEG. 5
• The only reported adverse effect in pediatric studies was diarrhea (occurring in 9 of 46 patients), which resolved with dose reduction. 6, 7

Safety Profile and Adverse Effects

Common Side Effects

• The most common adverse effects are abdominal distension, bloating, cramping, flatulence, and nausea, which are typically mild to moderate in severity. 2, 3
• Diarrhea occurs in 158 additional patients per 1,000 compared with placebo and resolves with dose reduction. 2
• All adverse events are consistent with expected laxative effects and rarely lead to discontinuation of therapy. 2

Long-Term Safety

• No clinically significant changes in electrolytes, calcium, glucose, BUN, creatinine, or serum osmolality have been observed with chronic PEG use. 2, 4
• Monthly laboratory monitoring over 6-month studies revealed no abnormal hematology, chemistry, or urinalysis findings. 2
• Treatment for up to 52 weeks maintains efficacy and tolerability, supporting long-term use when clinically indicated. 2

Contraindications and Precautions

• Do not use in patients with symptoms of bowel obstruction (nausea, vomiting, abdominal pain or distention). 3
• Discontinue immediately if hives or skin rashes occur, which are suggestive of an allergic reaction. 3
• Do not use if allergic to polyethylene glycol. 3
• The FDA label states PEG 3350 should not be used by children, though extensive pediatric evidence supports its safety and efficacy in this population. 3, 8, 7

Special Populations

Pregnancy and Postpartum

• Low-dose PEG 3350 has been used safely in a cohort of 225 pregnant individuals treated for constipation (FDA pregnancy category C). 2
• The AGA 2024 guideline explicitly states that osmotic laxatives such as PEG can be administered safely during pregnancy and the postpartum period, supporting its use as a first-line therapy. 2
• For postpartum constipation, PEG 3350 is preferred over stimulant laxatives as first-line therapy, alongside dietary fiber (~30 grams per day) and lactulose. 2

Post-Bariatric Surgery

• Patients who have undergone restrictive gastric surgery should use low-volume PEG 3350 preparations or allow a longer ingestion period to accommodate reduced gastric capacity. 2
• These patients should consume sugar-free beverages and liquid foods when taking PEG to prevent dumping syndrome. 2

Combination Therapy

• PEG 3350 can be safely combined with linaclotide (Constella) for patients with inadequate response to monotherapy, as the medications work through complementary mechanisms (osmotic water retention versus guanylate cyclase-C activation). 9
• Start with PEG 3350 alone at 17 grams daily as first-line therapy, then add linaclotide if response is inadequate after 2–4 weeks. 9
• Monitor for excessive loose stools or diarrhea when using both medications, as both can cause these side effects. 9

Treatment Duration and Maintenance

• The FDA label indicates PEG 3350 is intended for up to a two-week course of therapy for occasional constipation. 3
• However, guideline evidence supports continuing PEG 3350 as maintenance therapy given its durable response over 6 months, as 61.7% of patients may require additional laxative interventions within 30 days of stopping, suggesting many patients benefit from continued maintenance therapy. 2
• Once bowel movements normalize, continue maintenance dosing rather than stopping abruptly. 5

Common Clinical Pitfalls

• Inadequate liquid volume significantly reduces efficacy; always confirm patients are using at least 4 ounces (preferably 8 ounces) of mixing liquid. 2, 5
• Not confirming adequate daily fluid intake beyond the mixing liquid leads to treatment failure, as PEG requires water throughout the day to work osmotically. 2, 5
• Assuming treatment failure without first optimizing dose and ensuring compliance leads to premature discontinuation; always verify adequate hydration and allow at least 2 weeks for full effect. 2, 5
• Delaying rectal intervention beyond 3–4 days of no bowel movement increases the risk of fecal impaction; add suppositories or stimulant laxatives promptly. 5